Wrap-up Edition

That’s a wrap on #ASTRO22! The last issue of the Daily News for ASTRO 2022 features a special message from ASTRO President Jeff Michalski, MD, MBA, FASTRO, coverage on Wednesday's Cancer Breakthroughs session, abstract commentary and CME reminders.


Thursday Digital Daily Access the Digital Daily from day 5 at the 2022 ASTRO Annual Meeting.
Cancer Breakthroughs In one of the conference’s last but most highly anticipated sessions, Everett Vokes, MD, ASCO and Martha Matuszak, PhD from AAPM presented important findings from the ASCO and AAPM annual meetings. 
SBRT for HCC Phase II results comparing DEB-TACE to SBRT on patients with one to three HCC lesions with Childs-Pugh Class A liver disease.
Ablative RT for LAPC Retrospective analysis of consecutive LAPC patients treated with either 50 Gy in 5 fractions using a 0.35T MR Linac and online adaptive replanning or 67.5-75 Gy in 15-25 fractions using CBCT guidance and selective offline adaptive replanning.
Radiation for ICI in HCC Shu Jung Hsu, MD et al. presented their large retrospective study comparing immune checkpoint inhibitors (ICI) alone versus immune checkpoint inhibitors combined with radiation therapy (ICI-RT).
Potential Biomarker Bhavana Rai, MD, et al. presented their work on the use of circulating cell free DNA (cfDNA) as a minimally invasive and cost-effective potential biomarker that can be used for monitoring disease response.
HF Pelvic RT Ajeet Gandhi, MD, DNB, presented their work on hypofractionated pelvic radiation in intact cervical cancer. 
SBRT for VT Ian J. Gerard, MD, CM, PhD, and colleagues have embarked on ambitious studies of providing patients with refractory ventricular tachycardia (VT) an additional treatment option: SBRT.

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550


Connect With Us: